BridgeMD
Compares treatment options for Hematologic Malignancy
Official title Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
ClinicalTrials.gov ID: NCT07300735
What this study is testing
What is Loratadine?
Loratadine is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for hematologic malignancy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Adults 18 to 65 years old
- Receiving a G-CSF for one of the following indications: Treatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention...
- Patients with or without bone pain associated with G-CSF administration.
- Willingness to provide informed consent to participate in the study.
You likely can't join if
- Patients with solid tumors.
- Pregnant or breastfeeding women.
- Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.
- Patients with pre-existing bone disorders or receiving bone modifying agents
- Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.
- Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim
See the full eligibility criteria
- Adults 18 to 65 years old
- Receiving a G-CSF for one of the following indications: Treatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant
- Patients with or without bone pain associated with G-CSF administration.
- Willingness to provide informed consent to participate in the study.
- Patients with solid tumors.
- Pregnant or breastfeeding women.
- Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.
- Patients with pre-existing bone disorders or receiving bone modifying agents
- Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.
- Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim
- Patients who are unable to understand or provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Alexandria, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Alexandria, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.